1-3 of 3
Mei Huang, MS
Close
Sort by
Journal Articles

Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)

David S. Siegel, MD PhD, Jesus G. Berdeja, MD, Jeffrey R. Infante, MD, Jonathan L. Kaufman, MD, Michael (Luhua) Wang, MD, Thomas G. Martin, MD, Ruben Niesvizky, MD, Frederic J. Reu, MD, Sundar Jagannath, MD, Kanya Rajangam, MDPhD, Mei Huang, MS, Ravi Vij, MD
Journal: Blood
Blood (2014) 124 (21): 2134.
https://doi.org/10.1182/blood.V124.21.2134.2134
Published: 2014
Journal Articles

Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma

Ravi Vij, MD, Michael Wang, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Andrzej J. Jakubowiak, MD, PhD, Edward Kavalerchik, MD, Mei Huang, MS, David S. Siegel, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1965.
https://doi.org/10.1182/blood.V122.21.1965.1965
Published: 2013
Journal Articles

A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials.

David S. Siegel, MD, PhD, Michael Wang, M.D., Thomas G Martin, III, MD, Jeffrey R. Infante, MD, Jonathan L. Kaufman, MD, Kanya Ranjangam, MD, PhD, Mei Huang, MS, Elizabeth Bilotti, MSN, RN, Ravi Vij, MD
Journal: Blood
Blood (2012) 120 (21): 2962.
https://doi.org/10.1182/blood.V120.21.2962.2962
Published: 2012